2008, 100 pages (English). ISBN 978-2-940401-05-5

The ethical imperative of reducing health inequities, of closing the gap between the health of the poorest and those who are better off, demands the utmost collective effort.

In the last few years, product development partnerships (PDPs), a form of public-private partnerships (PPPs), have gained growing popularity as mechanisms for increasing access to essential drugs. As a result, an expanded pipeline of candidate drugs and vaccines for clinical trials has been established.

The scale of investments now needed to ensure that the best candidates go forward into clinical trials exceeds the funding capacity of any one donor in the public or philanthropic sectors and demands collective efforts.

• greater and more sustainable financing over the longer term;
• better mechanisms for coordination;
• strengthening of organizational capacities;
• creation of legislative, regulatory and service infrastructures and assessment;
• frameworks that will ensure that the new products are effective, safe, affordable and accessible to those in need and that they are taken up and used.

Health Partnerships Review aims to contribute to the debate about the future role of PDPs.

Table of Contents

Foreword/ Synthèse/ Sumário/ Resumen Stephen Matlin
Focusing collaborative efforts on research and innovation for the health of the poor
Canaliser les efforts collectifs sur la recherche et l'innovation, afin d'améliorer la santé des populations pauvres
Enfoque em esforços colaborativos em pesquisa e inovações em prol da saúde de populações pobres
Enfocar los esfuerzos colectivos en investigación e innovación para la salud de las poblaciones más pobres
The PDP approach
The new landscape of product development partnerships (PDPs) Stefanie Meredith and Elizabeth Ziemba
Public-private partnerships in health systems Sania Nishtar
Issues in assessing product development partnerships (PDPs) Lakshmi Sundaram
Technological and social innovation: a unifying new paradigm for global health Charles A Gardner, Tara Acharya and Derek Yach
Product development partnerships: public-private partnerships among unequal partners? Anna Wang
Research and development
Facing the dual challenge of developing both products and research capacities for neglected diseases Piero L Olliaro and Stephen C Wayling
The portfolio approach to successful product development in global health David Brown
The role of the health system in biotechnology in Brazil and Cuba Halla Thorsteinsdóttir
Sustainable (vaccine) development: the International AIDS Vaccine Initiative (IAVI) and capacity building Joanna Chataway and Rebecca Hanlin
Beyond market failures: IAVI and the organizational challenges of vaccine development Luigi Orsenigo, Stefano Brusoni and Eugenia Cacciatori
Clinical trials
Clinical trial site capacity for malaria product development Mary Moran, Javier Guzman, Anne-Laure Ropars, Margaret Jorgensen, Sarah Potter, Alina McDonald and Hiwot Haile-Selassie
Issues surrounding the implementation of multiple product development partnership clinical trials in developing countries Gita Ramjee
Collaborative approach to clinical trials Charles S Mgone and Pascoal Mocumbi
Running clinical trials in partnership with communities Anjali Gopalan
Bringing products to market
Getting diagnostics into countries Vinand M Nantulya
The control of neglected tropical diseases using access to available medicines through public-private partnerships Alan Fenwick, Peter J Hotez and David H Molyneux
The story of ASAQ: the first antimalarial product development partnership success Bernard Pécoul, Ann-Marie Sevcsik, John Amuasi, Graciela Diap and Jean-René Kiechel
Managing intellectual property for global health outcomes: the example of product development partnerships Robert Eiss
Regulatory strategies of product development partnerships: some perspectives Chris Hentschel, Jörg Möhrle and Jaya Banerji